## **Bibliography**

Hays RD, Wooley JM. The concept of clinically meaningful difference in health-related quality-of-life research. Pharmacoeconomics 2000;18(5):419-423.

Wells G, Beaton D, Shea B, et al. Minimum clinically important differences: review of methods. The Journal of Rheumatology 2001;28(2):406-412.

Basson R, et al. Summary of the recommendations on sexual dysfunctions in women. Journal of Sexual Medicine 2004;1(1):24-34.

Basson R, et al. Revised definitions of women's sexual dysfunction in women. Journal of Sexual Medicine 2004;1(1):40-48.

Heiman J, Guess MK, et al. Standards for clinical trials in sexual dysfunctions of women: research design and outcomes assessment. Journal of Sexual Medicine 2004;1(1):92-97.

Davis SR, Guay AT, et al. Endocrine aspects of sexual dysfunction. Journal of Sexual Medicine 2004;1(1):82-86.

Basaria S, Dobs, A. Safety and adverse effects of androgens: how to counsel patients. Mayo Clin Proc. 2004;79(suppl):S25-S32.

Anderson G, Limacher M, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. (Reprinted) JAMA, April 14, 2004; Vol 291, No 14:1701-1712

Rossouw JE, Anderson GL, Prentice, RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. (Reprinted) JAMA, July 17, 2002; Vol 288, No 3:321-333.

Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. (Reprinted) JAMA, June 25, 2003; Vol 289, No 24:3254-3263.

Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. British Journal of Cancer 2004;90:153-159.

Endogenous Hormones and Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute, August 20, 2003;Vol 95, No 16:1218-1226.

Manjer J, Johansson R, Berglund G, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes and Control 2003;14:599-607.